Diploid Genomics Launches with Healthier Capital Backing to Advance AI Analytics

Diploid Genomics, Inc. (DGI), a new enterprise focused on artificial intelligence-driven advanced genomics analytics, formally commenced operations on January 23, 2026. The company’s launch was secured through a key partnership with Healthier Capital, a specialized health-tech venture capital firm founded by Amir Dan Rubin, the former Chief Executive Officer of Amazon | One Medical. DGI is tasked with constructing a next-generation analytical platform designed to make health outcomes for complex pathologies more predictable, quantifiable, and actionable.

The operational framework for DGI integrates advanced AI models with high-resolution genomic sequencing, specialized medical imaging, and extensive patient health data sets. This convergence aims to generate diagnostic intelligence with superior accuracy for clinical researchers, health systems, and patients. Healthier Capital acted as a co-founder and the exclusive external financial contributor in DGI’s recently concluded Series Seed funding initiative, which closed in January. Rubin, who founded Healthier Capital in 2023 after leading One Medical through its $3.9 billion acquisition by Amazon in 2023, stated that the firm anticipates DGI's proprietary, AI-centric methodology will fundamentally transform disease diagnosis and subsequent therapeutic intervention development.

DGI benefits from immediate, substantial access to proprietary technical assets, providing a significant advantage at its inception. These assets include cutting-edge sequencing technology from PacBio and Oxford Nanopore, specialized high-performance computing infrastructure, and valuable genomic and imaging data originating from the J. Craig Venter Institute (JCVI), a non-profit research organization. The company is currently establishing its dedicated sequencing facility in San Diego, with plans to seek CLIA certification to ensure its AI-augmented sequencing services meet clinical-grade standards.

The leadership structure of DGI leverages deep expertise from JCVI, featuring Dr. J. Craig Venter, Anders Dale, Ph.D., and Eugene Myers, Ph.D. Dr. Venter is recognized for leading the effort to sequence the first draft of the human genome and for establishing Celera Genomics. Dr. Dale, appointed President of JCVI in April 2025, focuses on integrating quantitative imaging data with genomic information, drawing experience from major NIH-funded studies like the ABCD Study. Dr. Myers is noted in the bioinformatics community for his foundational work in developing the widely utilized BLAST bioinformatics tool. The company name, 'Diploid,' references the biological state of possessing two complete sets of chromosomes.